Recombinant Anti-SMC1A antibody [BL-205-2G8] (ab243875)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [BL-205-2G8] to SMC1A
- Suitable for: ICC, IHC-P, IP, WB
- Reacts with: Mouse, Human
Overview
-
Product name
Anti-SMC1A antibody [BL-205-2G8]
See all SMC1A primary antibodies -
Description
Rabbit monoclonal [BL-205-2G8] to SMC1A -
Host species
Rabbit -
Tested applications
Suitable for: ICC, IHC-P, IP, WBmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide within Human SMC1A aa 1200-1233 (C terminal). The exact sequence is proprietary. NP_006297.2 and Gene ID 8243.
Database link: Q14683 -
General notes
This product is sold under License from Bethyl Laboratories, Inc.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.8
Preservative: 0.09% Sodium azide
Constituents: 98% Borate buffered saline, 0.1% BSA -
Concentration information loading...
-
Purification notes
Recombinant antibody was purified from cell culture supernatant. -
Clonality
Monoclonal -
Clone number
BL-205-2G8 -
Isotype
IgG -
Research areas
Associated products
Applications
Our Abpromise guarantee covers the use of ab243875 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ICC | 1/100 - 1/500. | |
IHC-P | 1/100 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. | |
IP | Use at an assay dependent concentration. Use 20µl/mg lysate. |
|
WB | 1/1000. |
Target
-
Function
Involved in chromosome cohesion during cell cycle and in DNA repair. Central component of cohesin complex. The cohesin complex is required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The cohesin complex may also play a role in spindle pole assembly during mitosis. Involved in DNA repair via its interaction with BRCA1 and its related phosphorylation by ATM, or via its phosphorylation by ATR. Works as a downstream effector both in the ATM/NBS1 branch and in the ATR/MSH2 branch of S-phase checkpoint. -
Involvement in disease
Defects in SMC1A are the cause of Cornelia de Lange syndrome type 2 (CDLS2) [MIM:300590]; also known as Cornelia de Lange syndrome X-linked. CDLS is a clinically heterogeneous developmental disorder associated with malformations affecting multiple systems. CDLS is characterized by facial dysmorphisms, abnormal hands and feet, growth delay, cognitive retardation and various other malformations including gastroesophageal dysfunction and cardiac, ophthalmologic and genitourinary anomalies. -
Sequence similarities
Belongs to the SMC family. SMC1 subfamily. -
Domain
The flexible hinge domain, which separates the large intramolecular coiled coil regions, allows the heterotypic interaction with the corresponding domain of SMC3, forming a V-shaped heterodimer. The two heads of the heterodimer are then connected by different ends of the cleavable RAD21 protein, forming a ring structure. -
Post-translational
modificationsPhosphorylated by ATM upon ionizing radiation in a NBS1-dependent manner. Phosphorylated by ATR upon DNA methylation in a MSH2/MSH6-dependent manner. Phosphorylation of Ser-957 and Ser-966 activates it and is required for S-phase checkpoint activation. -
Cellular localization
Nucleus. Chromosome. Chromosome > centromere > kinetochore. Associates with chromatin. Before prophase it is scattered along chromosome arms. During prophase, most of cohesin complexes dissociate from chromatin probably because of phosphorylation by PLK, except at centromeres, where cohesin complexes remain. At anaphase, the RAD21 subunit of the cohesin complex is cleaved, leading to the dissociation of the complex from chromosomes, allowing chromosome separation. In germ cells, cohesin complex dissociates from chromatin at prophase I, and may be replaced by a meiosis-specific cohesin complex. The phosphorylated form on Ser-957 and Ser-966 associates with chromatin during G1/S/G2 phases but not during M phase, suggesting that phosphorylation does not regulate cohesin function. Integral component of the functional centromere-kinetochore complex at the kinetochore region during mitosis. - Information by UniProt
-
Database links
- Entrez Gene: 8243 Human
- Entrez Gene: 24061 Mouse
- Omim: 300040 Human
- SwissProt: Q14683 Human
- SwissProt: Q9CU62 Mouse
- Unigene: 211602 Human
-
Alternative names
- Chromosome segregation protein SmcB antibody
- DXS423E antibody
- KIAA0178 antibody
see all
Images
-
Formaldehyde-fixed HCT-116 (human colorectal carcinoma cell line) cells labeling SMC1A using ab243875 at 1/250 dilution in ICC/IF analysis. A HRP-conjugated goat anti-rabbit IgG was used as the secondary antibody. DAB staining
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SMC1A antibody [BL-205-2G8] (ab243875)
Formalin-fixed, paraffin-embedded human Breast carcinoma tissue stained for SMC1A using ab243875 at 1/250 dilution in immunohistochemical analysis. A HRP-conjugated goat anti-rabbit IgG was used as the secondary. DAB staining.
-
SMC1A was immunoprecipitated from 1 mg HEK-293T whole cell lysate with ab243875 at 20 µl per reaction Western blot was performed on the immunoprecipitate using ab243875 at 1/1000 dilution.
Lane 1: ab243875 IP in HEK-293T whole cell lysate.
Lane 2: Contol IgG in HEK-293T whole cell lysate.
Detection: Chemiluminescence with an exposure time of 10 seconds.
-
Western blot analysis using ab243875 at 1/1000 dilution.
Lane 1: HeLa whole cell lysate (15 µg).
Lane 2: HEK-293T whole cell lysate (15 µg).
Lane3: MCF7 whole cell lysate (15 µg).
Lane 4: HepG2 whole cell lysate (15 µg).
Lane 5: A549 whole cell lysate (15 µg).
Lane 6: SW620 whole cell lysate (15 µg).
Lane 7: SK whole cell lysate (15µg).
Lane 8: Jurkat whole cell lysate (15 µg).
Lane 9: TCMK-1 whole cell lysate (15 µg).
Lane 10: NIH/3T3 whole cell lysate (15 µg).
Lane 11: CT26 whole cell lysate (15 µg)
A HRP-conjugated goat anti-rabbit IgG antibody was used as the secondary. Detection: chemiluminescence with an exposure time of 10 seconds
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (0)
ab243875 has not yet been referenced specifically in any publications.